垫料管理对毒害艾美耳球虫疫苗虫株免疫效果的影响

为比较垫料管理对毒害艾美耳球虫疫苗虫株免疫效果的影响,采用谷壳和木屑为垫料,垫料厚度分别为1、2、4 cm,以及定期翻动垫料和不翻动垫料的管理方式对疫苗反应期鸡肠道病变程度和相对增重的影响,以及对攻虫后鸡肠道病变程度、相对增重和免疫保护效果的影响。在疫苗反应期,各免疫组的肠道病变轻微,相对增重与空白对照组无显著差异(P0.05);免疫21 d后攻虫,所有免疫组均能抵抗1×105个毒害艾美耳球虫强毒孢子化卵囊的攻击,而且肠道病变轻微,相对增重与空白对照组无显著差异(P0.05)。试验结果表明,厚垫料可提高毒害艾美耳球虫的免疫均匀性,免疫效果稍优于薄垫料。     

将乐县中小型规模化养猪场免疫程序情况及其优化方案

通过对将乐县中小型规模猪场免疫程序及免疫效果情况的调查,认为首次接种猪瘟、高致病性蓝耳病、口蹄疫疫苗时,可采用猪口蹄疫疫苗与高致病性蓝耳病疫苗同时注射,1周后再接种猪瘟疫苗,免疫效果较好。     

诺氟沙星多克隆抗体的制备

用合成的NFLX-BSA偶联物免疫成年獭兔,采用ELISA方法检测抗血清效价.结果表明:采用合成的NFLX-BSA偶联物免疫成年獭兔获得了高效价的抗血清.     

脂肪细胞膜免疫技术的研究进展

综述了脂肪细胞膜免疫的种类及其降低动物胴体脂肪的作用机理和效果,阐述了目前存在的问题,并展望了脂肪细胞膜免疫技术的应用前景。     

嗜水气单胞菌对框镜鲤免疫实验研究

嗜水气单胞菌是水产动物的常见致病菌,本研究利用在生理生化和PCR鉴定的基础上确定为嗜水气单胞菌,并经PCR和药物敏感性实验确定对多种抗菌药物具有耐药性的嗜水气单胞菌多重耐药株。用该菌株制备细菌疫苗对框镜鲤进行免疫实验,免疫方法采用浸洗2 min,1.5、3、6个月后分别进行注射攻毒,攻毒实验结果显示免疫保护率60%~95%,实验室安全性检测结果为安全可靠。该方法避免了逐尾鱼注射造成的较大的工作强度,为在生产实践中广泛应用预防多重耐药嗜水气单胞菌所引起的疾病奠定了基础。     

雏鸡早期新城疫弱毒疫苗与灭活疫苗联合免疫方法的研究

在鸡新城疫（ＮＤ）流行的地区，雏鸡早期应用弱毒疫苗和灭活疫苗联合免疫的方法，可以较好地控制ＮＤ的发生。作者对弱毒疫苗与灭活疫苗的单独免疫和联合免疫分八个试验组进行了试验，并对试验结果进行了分析比较。结果表明：Ｂ３（弱毒疫苗→＾１０日龄 灭活疫苗）组于３、６、１０、２０、３０、４０、６０日龄分别随机取样检测ＮＤＨＩ抗体效价，值为５．８３Ｌｏｇ２，与其他各试验组相比，效价高且平稳；于２０、４０、６０、     

某猪场猪口蹄疫免疫程序的调整及免疫效果评价

为探讨一种适合四川某猪场的猪口蹄疫免疫程序,笔者根据猪场的实际情况对原有免疫程序进行了调整,然后采集调整前和调整后不同日龄的猪血清,用ELISA和IHA进行抗体检测。结果显示:调整前3日龄、25日龄、50日龄、90日龄和120日龄猪的ELISA抗体阳性率分别为50%、30%、40%、50%、55%,IHA抗体阳性率分别为70%、54.54%、66.67%、70%和85%;调整后ELISA抗体阳性率分别为90%、35%、45.45%、61.11%和50%,IHA抗体阳性率分别为82.98%、83.33%、92.86%、95%和95%。可见调整后的免疫效果明显优于调整前,调整后的免疫程序为:25日龄首免,50日龄二免,90日龄三免,以后每3个月免疫一次。     

广西南宁市免疫控制狂犬病的效果观察

为控制狂犬病的流行,南宁市自2008年起连续5年强化犬的免疫。至2012年,犬平均免疫覆盖率为79.86%,犬群免疫抗体阳转率为86.53%,与2007年相比,人狂犬病病例下降了69.70%,发病县区下降了54.55%。结果显示,对犬持续实施大面积免疫,有效控制了人狂犬病。     

Perception of cattle farmers of the efficacy of east coast fever immunization in Southern Zambia

A study using a structured questionnaire was conducted to assess the perception of cattle farmers of the efficacy of East Coast fever (ECF) immunization in southern Zambia. One hundred and seventy-nine farmers from five districts in southern Zambia were interviewed. The majority of farmers (85%) perceived ECF immunization as being very effective and about half of them (51.4%) preferred immunization to other ECF control strategies. The study showed that the number of calves immunized was strongly associated with the farmer's perception of the benefits of immunization. There was no association between the number of calves immunized and the number of veterinary assistants in a given district or their transport situation. Overall mortality in ECF-immunized calves from various causes stood at 4.2%. Based on farmers' reports, the majority of these deaths seemed to have been caused by anaplasmosis, another tick-borne disease, and might have resulted from relaxation of tick control after ECF immunization. The reasons identified by farmers for not immunizing their animals included failure by immunizing teams to reach certain areas, not having calves of immunization age, and lack of money. These findings provide valuable information on how livestock farmers perceive and adopt new animal disease control strategies and the information could be useful in their planning and implementation.     

Protection against Toxoplasma gondii brain cyst formation in mice immunized with Toxoplasma gondii cytoskeleton proteins and Lactobacillus casei as adjuvant

The aim of the study was to evaluate the protection generated in mice against Toxoplasma gondii brain cyst burden by vaccination with T. gondii cytoskeleton proteins using Lactobacillus casei as adjuvant. One hundred and sixty-eight NIH mice were randomly allocated into eight groups of 21 mice each. Animals were immunized as follows: in group 1 with Toxoplasma lysate antigen (TLA) in Freund's modified adjuvant, containing L. casei (FMA), in group 2 with Toxoplasma cytoskeleton proteins (TCPs) in FMA, in group 3 with FMA, in group 4 with phosphate buffered saline (PBS), in group 5 with L. casei dead by heath (Lc), in group 6 with Freund's complete adjuvant (FCA), in group 7 with TLA in FCA, and in group 8 with TCP in FCA. Mean brain cyst burden (±S.E.M.) was assessed in mice 8 weeks after challenge with T. gondii Me49 strain (20 cysts per mouse). The percentages of reduction in cyst burden per brain (P < 0.01) as compared with the group 4 (control: mean 3181 ± 97.5) were 77.25% (724 ± 98) in group 1, 88.02% (381 ± 97.5) in group 2, 38.92% (1943 ± 130.3) in group 3, 44.31% (1771.4 ± 102) in group 5, 59.28% (1295.2 ± 99.1) in group 7 and 55.69% (1409.5 ± 89.9) in group 8. In order of importance, the best protection was obtained in groups 2, 1, 7, 8, 5 and 3. Noticeably the mice inoculated with L. casei alone showed a significant reduction in T. gondii brain cysts (P < 0.01), while those animals treated with FCA alone did not. Additionally, IgM anti-T. gondii antibody levels, as determined by ELISA 2 weeks after challenge, were highest in group 2 (P < 0.01) than in the other seven groups. Results suggest that T. gondii cytoskeleton proteins with L. casei as adjuvant constitute a good anti-toxoplasmosis vaccine candidate.